Verge HealthTech Fund

What Verge HealthTech Fund does

Verge HealthTech Fund is a Singapore-headquartered, globally operating early-stage venture capital firm founded in 2018 by Joseph Mocanu and Ed Deng. The firm invests at Pre-Seed to Series A in healthtech startups across six verticals: AI and Data Analytics, Next Generation Diagnostics, Breakthrough Smart Devices, Digital Health Platforms, Digital Therapeutics, and Healthcare SaaS. The portfolio currently spans 36 companies across 49 countries, including 22 lower-middle-income markets, with reported impact across 34.4 million lives.

The fund's offering extends beyond capital to hands-on clinical, regulatory, and commercial support. Partners include practicing clinicians, scientists, and former operators (e.g., Quattromed CEO Erki Mölder, Prudential MD Scarlett Chen, Health2Sync co-founder Ed Deng, Lifetrack COO Carl Nicholas Ng), enabling Verge to structure clinical trials and pilots through hospital partner networks and to guide founders on FDA/CE regulatory pathways. Geo-agnostic deployment is supported by partners based in Asia, Europe (Estonia), and the US, and by strategic accelerator partnerships such as the Eir Accelerator with Women's Health Hub Finland and pharma partners Bayer, Organon, and Orion.

Verge monetizes as a traditional venture capital fund, earning management fees on committed capital during the investment period and targeting long-term returns through capital gains on portfolio exits over a 7-10 year fund cycle. Specific fund size, AUM, management fee rate, and LP composition are not publicly disclosed. The team comprises ten people across investment, portfolio management, and finance/marketing functions, and the firm maintains an active public presence through LinkedIn, conference participation, accelerator partnerships, and a direct "Submit Pitch" channel on its website.

Name

Verge HealthTech Fund

Legal name

Verge HealthTech Fund

Website

https://vergecm.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Verge HealthTech Fund is a Singapore-based early-stage venture capital firm founded in 2018 that invests at Pre-Seed to Series A in global healthtech startups across AI, diagnostics, smart devices, digital health, digital therapeutics, and healthcare SaaS, offering clinical and regulatory expertise alongside capital.

Ownership category

akta.pro rank

Product category

Venture Capital

NAICS

Open-End Investment Funds (525910)

SIC

Investment Advice (6282)

akta.pro primary industry

Early-Stage Venture Capital (Series A/B) (FSANAAAB)

akta.pro secondary industry

Healthcare Access & Life Sciences Impact Funds (FSANAJAI)

Keywords

• Venture capital investing
• Healthtech investment
• Early-stage funding
• Healthcare venture capital
• Startup investment

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Venture Capital Returns: Verge HealthTech Fund generates returns through capital gains on portfolio company exits, including IPOs, acquisitions, and secondary sales. As an early-stage VC fund, returns are realized over 7-10 year fund cycles through successful portfolio company outcomes.
2. Management Fees: VC funds typically charge 1.5-2% annual management fees on committed capital during the investment period, with potential for reduced fees in later years.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Verge HealthTech Fund is a global early-stage healthtech venture capital fund that makes equity investments in health technology startups from Pre-Seed to Series A stages, on a geo-agnostic basis. The fund provides capital alongside clinical trial structuring, regulatory pathway guidance (FDA/CE), global commercialization support, and hands-on validation through hospital partner networks, with a portfolio of 36 companies across 49 countries impacting 34+ million lives.

Product overview

Verge HealthTech Fund is a global early-stage healthtech venture capital fund that provides investment funding and strategic support to health technology startups. Rather than offering a technology product platform, the fund's offering consists of venture capital investment (Pre-Seed to Series A), clinical and regulatory expertise, global commercialization support, hands-on validation through hospital partner networks, and access to a global ecosystem of companies, investors, and institutions. The fund does not offer discrete technology products or SaaS platforms; its portfolio comprises 36 portfolio companies across various healthtech verticals including AI and data analytics, next-generation diagnostics, smart medical devices, digital health platforms, digital therapeutics, and healthcare SaaS.

Differentiator

Problem solved

Functional benefit

Products and services

• Healthtech Venture Capital Investment
• Portfolio Support Services

Quantifiable outcome

• 34+ million lives impacted across global portfolio
• +2 more outcomes

Named customers10 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Five partnerships are on record, tiered flagship and core.

• Women's Health Hub FinlandflagshipStrategic or Co-development Partner · 4 June 2026Verge HealthTech Fund is a key member of the international investor network backing the Eir Accelerator, a dedicated women's health startup program established by Women's Health Hub Finland. The six-month acceleration program supports early-stage femtech and women's health startups from the Nordics and wider Europe.
• BayercoreStrategic or Co-development PartnerBayer is a pharmaceutical partner involved with the Eir Accelerator program backed by Verge HealthTech Fund, helping portfolio companies generate clinical evidence and build partnerships.
• OrganoncoreStrategic or Co-development PartnerOrganon is a pharmaceutical partner involved with the Eir Accelerator program backed by Verge HealthTech Fund, supporting women's health startup development.
• OrioncoreStrategic or Co-development PartnerOrion is a pharmaceutical partner involved with the Eir Accelerator program backed by Verge HealthTech Fund, providing regulatory and commercial expertise for portfolio companies.
• MIT SolveflagshipStrategic or Co-development PartnerMIT Solve collaborates with Verge portfolio company ThinkMD on the Future Health Challenge, which awarded ThinkMD the USD 200,000 grand prize at the World Health Assembly in Geneva.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• StartUp Health: StartUp Health is a global early-stage healthtech venture fund and accelerator that holds a portfolio of health technology companies with an impact and moonshot lens. Directly comparable as both operate early-stage, globally distributed healthtech investing with mission-driven positioning.
• Section32: Section32 is a healthcare-focused early-stage venture fund founded by former Google Ventures partner Bill Maris. Both Verge and Section32 invest early-stage exclusively in healthtech and biotech, with comparable deal sizes and operating-partner support models.
• Lux Capital: Lux Capital is an early-stage venture fund with a strong healthtech, biotech, and frontier-tech focus, investing at Series A and earlier. Comparable in stage, thesis-driven specialization, and willingness to back scientifically complex founders.
• Kickstart Ventures: Kickstart Ventures is an early-stage VC backed by Ayala Corporation that invests in healthtech, fintech, and emerging technology across Southeast Asia. Comparable as both funds invest early-stage healthtech in Asia and have co-invested in Lifetrack Medical Systems alongside Verge.
• Plug and Play Tech Center: Plug and Play operates global healthtech-focused accelerator and venture programs with corporate partners across pharma and insurance. Comparable in early-stage healthtech deal flow, corporate co-investor engagement, and global platform footprint.
• Antler: Antler is a global early-stage venture fund that backs pre-seed and seed founders across multiple geographies including Asia, Europe, and the US. Comparable in stage, geo-agnostic thesis, and active founder support model, though Antler is sector-agnostic where Verge specializes in healthtech.

Broad incumbents

• Khosla Ventures: Khosla Ventures is a large early-stage venture firm with a notable healthtech and biotech practice alongside AI and clean tech. Overlaps with Verge in pre-seed/seed healthtech investing but operates at much larger fund scale and broader sector remit.
• ARCH Venture Partners: ARCH is a leading early-stage biotech and healthtech venture firm that has backed foundational companies like Illumina and GRAIL. Comparable early-stage science-heavy thesis but with materially larger fund size and deeper biotech specialization.
• Optum Ventures: Optum Ventures is the corporate venture arm of Optum/UnitedHealthGroup that invests early-stage in healthtech and digital health globally. Comparable in stage and sector focus but with substantially larger cheque sizes and strategic distribution advantages through UnitedHealth.
• Bain Capital Life Sciences: Bain Capital Life Sciences is a large healthcare-focused private equity and venture franchise investing across biopharma, medtech, and digital health. Comparable in sector focus but operates at growth-stage scale and is significantly larger than Verge's pre-seed/Series A focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/verge-healthtech-fund

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments27 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Verge HealthTech Fund